Skip to main content

Universal cancer vaccine being developed

Inhibiting the telomerase enzyme, present in most cancers, may prevent cell division but some scientists warn of "more harm than good."

Brought to you byScience Now
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00

LONDON, August 30 (SPIS MedWire). A universal vaccine for all cancers is being developed, according to a report in Nature Medicine. The vaccine targets the enzyme telomerase, which is present in most cancers; inhibition of telomerase means that the cells are unable to divide and therefore die. Professor Eli Gilboa, from Duke University Medical Center in Durham, New Carolina, commented, "The thinking has been that because every cancer is different … each cancer has its own specific set of antigens that must be used for a vaccine. We're looking for a universal antigen - one antigen to try to treat every cancer patient." The team modified cells to carry part of the telomerase protein, which activated the immune system to attack cancer cells that produced telomerase. Laboratory experiments showed the vaccine was capable of slowing the growth of skin, breast and bladder cancers when implanted into mice, and was also ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Related articles background image
August 2026 Digest cover
August 2026

Epic Fail: Sea-Monkeys Sabotage Fieldwork

When Barry Hicks set out to photograph thrombolites, thousands of unexpected visitors photobombed his underwater images.

View this Issue
Improving rAAV Production for Viral Vector Manufacturing

Improving rAAV Production for Viral Vector Manufacturing

cytiva logo
Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Miltenyi
Scientist holding a clear 384-well PCR microplate in a laboratory

What Dictates PCR Success Before Amplification Begins?

Integra Logo
Overcoming Immunotherapy Resistance in Liver Cancer

Overcoming Immunotherapy Resistance in Liver Cancer

Axion Biosystems

Products

Sino Biological Logo

Sino Biological Launches European Newsletter Campaign with Exclusive Welcome Gifts

Sino Biological Logo

Sino Biological Launches SuperNuclease ® Pro with Free Trial Program

Sino Biological Logo

Sino Biological Launches Precisely Characterized Full-Length p-Tau217 Protein to Advance Next-Generation Alzheimer’s Biomarker Assay Development

A photo of a scientist placing the Resipher device on a 96-well plate.

Resipher: Continuous Live-Cell Mitochondrial Respiration Monitoring in 96-Well Plates

Lucid Scientific logo